Thomas Martin, Md
Clinical trials sponsored by Thomas Martin, Md, explained in plain language.
-
Gene-Edited immune cells take on Hard-to-Treat myeloma in early trial
Disease control TerminatedThis early-phase trial tests a new treatment for multiple myeloma that has come back or not responded to standard therapies. The treatment uses a patient's own immune cells (T cells) that are modified in the lab using CRISPR gene editing to recognize and attack cancer cells. Abou…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat myeloma
Disease control OngoingThis early-phase trial is testing a new type of immune cell therapy called Anti-BCMA CAR-T cells in 5 adults with multiple myeloma that has come back or not responded to at least three prior treatments. The therapy involves collecting a patient's own immune cells, modifying them …
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC